Follicular Lymphoma: Pathology, Diagnosis, and Comprehensive Management
Pathology
Follicular lymphoma diagnosis requires an excisional lymph node biopsy—core biopsies should only be used when easily accessible nodes are unavailable, and fine needle aspiration is inadequate for reliable diagnosis 1, 2.
The histological grading system classifies FL based on centroblast count per high-power field:
- Grade 1: ≤5 blasts/HPF
- Grade 2: 6-15 blasts/HPF
- Grade 3A: >15 blasts/HPF with centroblasts and intermingled centrocytes
- Grade 3B: >15 blasts/HPF with pure sheets of blasts 1
Grades 1,2, and 3A are treated as indolent disease, while grade 3B is managed as aggressive lymphoma 2. Expert haematopathology review is advised for grade 3A/3B cases with atypical infiltration patterns 2.
Additional tissue should be stored (fresh frozen and paraffin-fixed) for future molecular analyses 1. While emerging biomarkers like the m7-FLIPI clinicogenetic risk score and gene expression profiling show promise, these are not yet suitable for routine clinical decision-making 1, 2.
Diagnosis and Staging
PET-CT is recommended for routine staging and is mandatory to confirm localized stage I/II disease before involved-site radiotherapy (ISRT) 1, 3.
Required Initial Work-up:
- Imaging: PET-CT of neck, thorax, abdomen (and pelvis per older guidelines) 1, 2
- Bone marrow: Aspirate and biopsy 1, 2
- Laboratory tests:
- Complete blood count
- LDH, β2-microglobulin, uric acid
- Immunoglobulin levels
- HIV, HBV, HCV screening 1
Staging follows the Ann Arbor classification system 1.
Risk Stratification
Two validated prognostic indices guide treatment decisions:
FLIPI (original) uses 5 parameters:
- Age >60 years
- Stage III-IV
4 nodal regions
- Elevated LDH
- Hemoglobin <12 g/dL
FLIPI-2 incorporates:
- Age >60 years
- Bone marrow involvement
- Largest lymph node >6 cm
- Elevated β2-microglobulin
- Hemoglobin <12 g/dL 1
Risk categories: low (0-1 factors), intermediate (2 factors), high (≥3 factors) 1.
Stage-Specific Management
Localized Disease (Stage I-II): 10-15% of Patients
For limited low tumor burden stage I-II disease, ISRT (24-30 Gy) is the preferred curative-intent approach 1, 2.
The optimal regimen combines ISRT with single-agent rituximab, providing the best balance between efficacy and side effects 1. Combination with rituximab-chemotherapy improves PFS compared to RT alone, though single-agent rituximab is preferred to minimize toxicity 1.
A reduced 2×2 Gy schedule may be used in special anatomic locations (lacrimal glands, parotid glands) to minimize side effects, though it is less durably effective 1.
Watch-and-wait or rituximab monotherapy may be considered in selected cases with limited life expectancy or when large abdominal radiation fields would be required 1.
Critical caveat: Stage I-II patients with high tumor burden, adverse prognostic features, or disease in sites where ISRT is not feasible (lung, liver) should receive systemic therapy as indicated for advanced stages 1.
Advanced Disease (Stage III-IV): 85-90% of Patients
The natural history includes spontaneous regression in 10-20% of cases, with highly variable clinical courses 1.
Asymptomatic, Low Tumor Burden
Watch-and-wait is the appropriate strategy for asymptomatic patients with low tumor burden 3, 4. This approach recognizes the indolent nature and lack of curative therapy while avoiding unnecessary treatment toxicity.
Rituximab monotherapy is an acceptable alternative 3.
Symptomatic or High Tumor Burden
Immunochemotherapy with anti-CD20 antibodies (rituximab or obinutuzumab) combined with chemotherapy (CHOP, CVP, or bendamustine) is recommended, followed by 2 years of anti-CD20 maintenance therapy 1, 3.
The combination of immunochemotherapy followed by maintenance has become standard based on improved PFS outcomes 1.
Relapsed/Refractory Disease
Repeat biopsy is essential at relapse to exclude histologic transformation to aggressive lymphoma 5.
Management is individualized based on:
- Timing of relapse (early progression within 24 months of first-line therapy carries poor prognosis)
- Tumor burden
- Prior treatment history
- Patient fitness 3, 5
For second-line therapy, lenalidomide-rituximab-based triplet combinations are preferred in most settings 5.
Novel immunotherapies including bispecific antibodies and CAR T-cell therapy are emerging as options for third-line and later disease 3, 5. Autologous stem cell transplantation remains valid for young patients with early relapse who are sensitive to immunochemotherapy 3.
Follow-up Considerations
Given the generally favorable long-term prognosis, treatment selection must carefully balance efficacy against late sequelae including second malignancies and organ damage 4. Thorough follow-up is necessary to detect these complications 4.
Common pitfall: Failing to confirm true localized disease with PET-CT before committing to radiotherapy-based curative approaches—inadequate staging may result in inappropriate treatment selection 1, 2.